Loading...

Cetuximab in locally advanced head-and-neck cancer: defining the population

Encouraging data for targeted therapy in head-and-neck squamous cell carcinoma are opening new options for treatment. Phase III trials of cetuximab, an antibody directed against the epidermal growth factor receptor (egfr) have demonstrated benefit in the locally advanced and metastatic settings. Rec...

Full description

Saved in:
Bibliographic Details
Main Author: Ho, C.
Format: Artigo
Language:Inglês
Published: Multimed Inc. 2010
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2913829/
https://ncbi.nlm.nih.gov/pubmed/20697514
Tags: Add Tag
No Tags, Be the first to tag this record!